Collagenase 3 - Pipeline Review, H2 2020
Collagenase 3 - Pipeline Review, H2 2020
Summary
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Collagenase 3 - Pipeline Review, H2 2020, outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Infectious Disease and Respiratory which include indications Osteoarthritis, Allergic Asthma, Alphavirus Infections, Arthralgia (Joint Pain), Arthritis, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Edema, Knee Osteoarthritis, Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ), Myocardial Infarction, Osteoarthritis Pain and Seasonal Allergic Rhinitis.
Furthermore, this report also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
- The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it?s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of content
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Overview
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development
Aquilus Pharmaceuticals Inc
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
Pharmahungary Group
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-152 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profil
CONTACT US:
276 5th Avenue, New York, NY 10001, United States
International: +1(646)-781-7170 / +91 8087042414
Email: [email protected]
Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store
Chikungunya Fever Market Research Report: By Diagnosis (ELISA Based Assays, Serological Tests, Virological Tests), Treatment (Allopathy, Homeopathy), End User (Hospitals And Clinics, Academic Institutes, Research Laboratories) - Global Forecast till 2027Global Chikungunya Fever Market - OverviewChikungunya fever is a disease caused by mosquito bites.
The disease is transmitted via human to human by the bites of female mosquitoes that are infected.
Incidents such as this is projected to boost the market growth across the globe during the forecasted period.Globally, more than 60 countries had reported Chikungunya fever cases for all regions including Africa continents, Americas, Europe, and Asia Oceanic.
According to the World Health Organization in 2016, there were 349 936 suspected with more than 146 914 laboratory confirmed cases of chikungunya reported to the (Pan American Health Organization) PAHO regional office.
Countries such as Brazil reported the most severe cases with 265 000 suspected cases followed by Bolivia and Colombia at 19 000 suspected cases.The global chikungunya fever market is expected to grow at a CAGR of 5.8% during the forecast period.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/4694 Global Chikungunya Fever Market - Regional AnalysisThe global chikungunya fever market is divided into four regions namely Americas, Europe, Asia Pacific and the Middle East and Africa.The Americas dominate the global chikungunya fever market owing to a strong government support for research & development, high healthcare spending, and large patient population.
A well-developed healthcare sector, high healthcare spending and huge geriatric & patient population will boost the market in North America.
Global Chikungunya Fever Market - OverviewChikungunya fever is a disease caused by mosquito bites.
The disease is transmitted via human to human by the bites of female mosquitoes that are infected.
As per the World Health Organization (WHO), the disease mostly occurs in Asian countries such as the Indian subcontinent and other African regions.
Request Sample Copy:https://www.marketresearchfuture.com/sample_request/4694Globally, more than 60 countries had reported Chikungunya fever cases for all regions including Africa continents, Americas, Europe, and Asia Oceanic.
According to the World Health Organization in 2016, there were 349 936 suspected with more than 146 914 laboratory confirmed cases of chikungunya reported to the (Pan American Health Organization) PAHO regional office.
Global Chikungunya Fever Market - Regional AnalysisThe global chikungunya fever market is divided into four regions namely Americas, Europe, Asia Pacific and the Middle East and Africa.The Americas dominate the global chikungunya fever market owing to a strong government support for research & development, high healthcare spending, and large patient population.
This report studies the global Chikungunya Fever Drugs market status and forecast, categorizes the global Chikungunya Fever Drugs market size (value & volume) by manufacturers, type, application, and region.
This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia).
The major manufacturers covered in this report • Abivax SA• Arno Therapeutics Inc• Bharat Biotech International Ltd• Ennaid Therapeutics LLC• Etubics Corp• Hawaii Biotech Inc• Indian Immunologicals Ltd• Inovio Pharmaceuticals Inc• Integral Molecular Inc• Integrated BioTherapeutics Inc• Moderna Therapeutics Inc• Mymetics Corp• Nanotherapeutics Inc• Paradigm Biopharmaceuticals Ltd Download Free Sample Report @ https://www.radiantinsights.com/research/global-chikungunya-fever-drugs-market-research-report-2019/request-sample Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering• North America• Europe• China• Japan• Southeast Asia• India We can also provide the customized separate regional or country-level reports, for the following regions:• North America• United States• Canada• Mexico• Asia-Pacific• China• India• Japan• South Korea• Australia• Indonesia• Singapore• Rest of Asia-Pacific• Europe• Germany• France• UK• Italy• Spain• Russia• Rest of Europe• Central & South America• Brazil• Argentina• Rest of South America• Middle East & Africa• Saudi Arabia• Turkey• Rest of Middle East & Africa Browse Full Research Report with TOC @ https://www.radiantinsights.com/research/global-chikungunya-fever-drugs-market-research-report-2019 On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into• Chikungunya Vaccine• Monoclonal Antibodies• Pentosan Polysulfate Sodium• Synthetic Peptides• OthersOn the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including• Clinc• Research Institution• Hospital The study objectives of this report are:• To analyze and study the global Chikungunya Fever Drugs capacity, production, value, consumption, status (2013-2017) and forecast (2018-2025);• Focuses on the key Chikungunya Fever Drugs manufacturers, to study the capacity, production, value, market share and development plans in future.• Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.• To define, describe and forecast the market by type, application and region.• To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.• To identify significant trends and factors driving or inhibiting the market growth.• To analyze the opportunities in the market for stakeholders by identifying the high growth segments.• To strategically analyze each submarket with respect to individual growth trend and their contribution to the market• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market• To strategically profile the key players and comprehensively analyze their growth strategies.
Read all Reports of this category @ https://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare About Radiant Insights Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements.
It assists and facilitate organizations and individuals procure market research reports, helping them in the decisions making process.
The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets.
Asthma can sometimes be stressful and challenging.
But it does not have to be a limiting condition.
We have selected the best asthma blogs that include useful tips and suggestions to help you keep your asthma symptoms under control.allergic asthma and covid-19 allergic asthma and covid-19 vaccine asthma after covid-19 recovery asthma and copd in hospitalized covid-19 patients asthma and covid 19 google scholar asthma and covid 19 how to tell the difference asthma and covid 19 vaccine uk asthma and covid-19 latest research asthma diagnosis test asthma diseasehttps://usamedilife.com/product/aerocort-forte-rotacaps/
